InnoTherapy Inc (246960) - Total Liabilities
Based on the latest financial reports, InnoTherapy Inc (246960) has total liabilities worth ₩50.78 Billion KRW (≈ $34.41 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore InnoTherapy Inc (246960) investment intensity to see how much of total assets are deployed in long-term investments.
InnoTherapy Inc - Total Liabilities Trend (2015–2024)
This chart illustrates how InnoTherapy Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 246960 asset base.
InnoTherapy Inc Competitors by Total Liabilities
The table below lists competitors of InnoTherapy Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Adriatic Metals
LSE:ADT1
|
UK | GBX192.27 Million |
|
Salutica Bhd
KLSE:0183
|
Malaysia | RM16.82 Million |
|
Medifron DBT Co. Ltd
KQ:065650
|
Korea | ₩86.61 Billion |
|
ChowChow Cloud International Holdings Limited
NYSE MKT:CHOW
|
USA | $33.73 Million |
|
Tira Austenite Tbk
JK:TIRA
|
Indonesia | Rp227.30 Billion |
|
Vakif Menkul Kiymet Yatirim Ortakligi AS
IS:VKFYO
|
Turkey | TL2.05 Million |
|
Smartiks Yazilim AS
IS:SMART
|
Turkey | TL107.22 Million |
|
Mg Internation
PA:ALMGI
|
France | €18.94 Million |
Liability Composition Analysis (2015–2024)
This chart breaks down InnoTherapy Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is InnoTherapy Inc's balance sheet to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.98 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.96 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.67 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how InnoTherapy Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for InnoTherapy Inc (2015–2024)
The table below shows the annual total liabilities of InnoTherapy Inc from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩8.54 Billion ≈ $5.79 Million |
-24.12% |
| 2023-12-31 | ₩11.26 Billion ≈ $7.63 Million |
-36.66% |
| 2022-12-31 | ₩17.77 Billion ≈ $12.04 Million |
-18.50% |
| 2021-12-31 | ₩21.80 Billion ≈ $14.78 Million |
+394.60% |
| 2020-12-31 | ₩4.41 Billion ≈ $2.99 Million |
+105.02% |
| 2019-12-31 | ₩2.15 Billion ≈ $1.46 Million |
+29.66% |
| 2018-12-31 | ₩1.66 Billion ≈ $1.12 Million |
+49.76% |
| 2017-12-31 | ₩1.11 Billion ≈ $750.44K |
+15.60% |
| 2016-12-31 | ₩957.90 Million ≈ $649.16K |
-93.32% |
| 2015-12-31 | ₩14.34 Billion ≈ $9.72 Million |
-- |
About InnoTherapy Inc
SCL Science Inc. produces medical hemostatic agents using biomimetic technology. Its products include BiMM (Bio-inspired Medical Materials) that reacts immediately with blood; Endoseal, which is used for specialized indication of gastrointestinal bleeding; InnoSeal, a hemostatic agent that is used in various surgical fields, such as cardiology, radiology, and neurosurgery; Jelly Seal, a hemostasi… Read more